Breakthrough injection aims to free patients from daily pill burden
NCT ID NCT04701203
Summary
This trial tested whether a daily injection called TransCon PTH could help adults with hypoparathyroidism better control their blood calcium levels. For the first 26 weeks, some participants received the real injection while others received a placebo, and neither they nor their doctors knew which. The main goal was to see if people could maintain normal calcium levels while stopping their usual high doses of vitamin D and calcium pills.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ascendis Pharma Investigational Site
San Francisco, California, 94143, United States
-
Ascendis Pharma Investigational Site
Chicago, Illinois, 60637, United States
-
Ascendis Pharma Investigational Site
Rochester, Minnesota, 55905, United States
-
Ascendis Pharma Investigational Site
Reno, Nevada, 89511, United States
-
Ascendis Pharma Investigational Site
New York, New York, 10032, United States
-
Ascendis Pharma Investigational Site
Greenville, North Carolina, 27834, United States
-
Ascendis Pharma Investigational Site
Austin, Texas, 78731, United States
-
Ascendis Pharma Investigational Site
Fort Worth, Texas, 76132, United States
-
Ascendis Pharma Investigational Site
Spokane, Washington, 99204, United States
-
Ascendis Pharma Investigational Site
Halifax, Nova Scotia, B3H 2Y9, Canada
-
Ascendis Pharma Investigational Site
Oakville, Ontario, L6M 1M1, Canada
-
Ascendis Pharma Investigational Site
Québec, Quebec, G1V 4G2, Canada
-
Ascendis Pharma Investigational Site
Copenhagen, Capital Region, 2100, Denmark
-
Ascendis Pharma Investigational Site
Aarhus, Central Jutland, 8200, Denmark
-
Ascendis Pharma Investigational Site
Dresden, Saxony, 01307, Germany
-
Ascendis Pharma Investigational Site
Szeged, Csongrád megye, 6720, Hungary
-
Ascendis Pharma Investigational Site
Budapest, 1083, Hungary
-
Ascendis Pharma Investigational Site
Bologna, Emilia-Romagna, 40138, Italy
-
Ascendis Pharma Investigational Site
Rome, Lazio, 00128, Italy
-
Ascendis Pharma Investigational Site
Pisa, Piacenza, 56126, Italy
-
Ascendis Pharma Investigational Site
Oslo, 0176, Norway
Conditions
Explore the condition pages connected to this study.